Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.40 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 6/20 | 0.37 |
| ▸ | TEK | Q02763 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168762 | 0.90 | RAF1 (0.38) | TTBK1TTBK2RAF1BRAFKDR | |
| SCHEMBL4164914 | 0.90 | RIPK1 (0.44) | RAB9ANPC1SMN1; SMN2TTBK1TTBK2 | |
| SCHEMBL4175186 | 0.90 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2TTBK1TTBK2 | |
| SCHEMBL4166852 | 0.80 | RIPK1 (0.45) | TTBK1TTBK2RAF1BRAFKDR | |
| SCHEMBL4164886 | 0.80 | KDR (0.41) | RAF1BRAFKDRTEKHTT | |
| SCHEMBL4161466 | 0.79 | KDR (0.53) | TTBK1TTBK2RAF1BRAFKDR | |
| SCHEMBL5447181 | 0.74 | RAF1 (0.44) | RAF1BRAFKDRTEKPDE10A | |
| SCHEMBL5456254 | 0.74 | RAF1 (0.44) | RAF1BRAFKDRTEKPDE10A | |
| SCHEMBL5468920 | 0.73 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12016736 | 0.72 | RAB9A (0.41) | RAB9ANPC1SMN1; SMN2TTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | claimed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | claimed |
| EP-1675849-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | claimed |
| WO-2005042520-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1675849-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005042520-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082404-A1 | BENZIMIDAZOLES | TIE1, KDR, FLT1 | RAB9A 3539/4885NPC1 4812/4885SMN1; SMN2 2539/4885 |
| US-20070066660-A1 | Benzimidazolyl derivatives | TIE1, ECE2, ABL1 | RAB9A 2407/4885NPC1 4854/4885SMN1; SMN2 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.